S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home

Apellis Pharmaceuticals (APLS) Stock Forecast, Price & News

$43.77
-3.23 (-6.87%)
(As of 09/22/2023 ET)
Compare
Today's Range
$43.02
$47.76
50-Day Range
$23.65
$52.46
52-Week Range
$19.83
$94.75
Volume
3.27 million shs
Average Volume
2.38 million shs
Market Capitalization
$5.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.13

Apellis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
51.1% Upside
$66.13 Price Target
Short Interest
Healthy
10.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.17mentions of Apellis Pharmaceuticals in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$10.57 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.89) to ($2.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

72nd out of 963 stocks

Pharmaceutical Preparations Industry

18th out of 458 stocks


APLS stock logo

About Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS Price History

APLS Stock News Headlines

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Robert W. Baird Remains a Buy on Apellis Pharmaceuticals (APLS)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Up to $43.31
Apellis' Waltham office to lose 175 in layoffs
See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Company Calendar

Last Earnings
7/31/2023
Today
9/24/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
Fax
N/A
Employees
767
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$66.13
High Stock Price Forecast
$141.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+51.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
15 Analysts

Profitability

Net Income
$-652,170,000.00
Net Margins
-356.02%
Pretax Margin
-356.37%

Debt

Sales & Book Value

Annual Sales
$75.42 million
Book Value
$1.54 per share

Miscellaneous

Free Float
108,907,000
Market Cap
$5.15 billion
Optionable
Not Optionable
Beta
1.08

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Cedric Francois M.D. (Age 51)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $1.2M
  • Dr. Pascal Deschatelets Ph.D. (Age 53)
    Co-Founder & Chief Scientific Officer
    Comp: $688.05k
  • Mr. Alec  Machiels J.D.Mr. Alec Machiels J.D. (Age 50)
    MBA, Co-Founder & Director
    Comp: $72.5k
  • Mr. Timothy E. SullivanMr. Timothy E. Sullivan (Age 52)
    CFO & Treasurer
    Comp: $716.41k
  • Mr. David O. Watson Esq.Mr. David O. Watson Esq. (Age 50)
    J.D., Gen. Counsel
    Comp: $675.35k
  • Mr. Adam J. TownsendMr. Adam J. Townsend (Age 46)
    Chief Commercial Officer
    Comp: $701.61k
  • Ms. Nur  NicholsonMs. Nur Nicholson (Age 54)
    Chief Technical Operations Officer
  • Mr. James G. Chopas CPA (Age 57)
    VP, Corp. Controller & Chief Accounting Officer
  • Ms. Meredith Kaya
    Sr. VP, Investor Relations & Strategic Fin.
  • Ms. Karen  LewisMs. Karen Lewis (Age 51)
    Chief People Officer













APLS Stock - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings
or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price forecast for 2023?

15 analysts have issued twelve-month target prices for Apellis Pharmaceuticals' shares. Their APLS share price forecasts range from $29.00 to $141.00. On average, they expect the company's share price to reach $66.13 in the next year. This suggests a possible upside of 51.1% from the stock's current price.
View analysts price targets for APLS
or view top-rated stocks among Wall Street analysts.

How have APLS shares performed in 2023?

Apellis Pharmaceuticals' stock was trading at $51.71 on January 1st, 2023. Since then, APLS shares have decreased by 15.4% and is now trading at $43.77.
View the best growth stocks for 2023 here
.

Are investors shorting Apellis Pharmaceuticals?

Apellis Pharmaceuticals saw a decrease in short interest in August. As of August 31st, there was short interest totaling 12,310,000 shares, a decrease of 10.5% from the August 15th total of 13,750,000 shares. Based on an average daily volume of 4,640,000 shares, the days-to-cover ratio is currently 2.7 days.
View Apellis Pharmaceuticals' Short Interest
.

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our APLS earnings forecast
.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) posted its quarterly earnings data on Monday, July, 31st. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.35) by $0.33. The business earned $95 million during the quarter, compared to analyst estimates of $70.38 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 212.82% and a negative net margin of 356.02%. The business's revenue for the quarter was up 482.8% on a year-over-year basis. During the same period in the prior year, the business posted ($1.46) EPS.

What ETFs hold Apellis Pharmaceuticals' stock?
What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.88%), State Street Corp (1.94%), Jennison Associates LLC (1.67%), Geode Capital Management LLC (1.27%), Point72 Asset Management L.P. (1.05%) and Artal Group S.A. (0.89%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan, Victoria L Brown and Victoria L Brown.
View institutional ownership trends
.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $43.77.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $5.15 billion and generates $75.42 million in revenue each year. The company earns $-652,170,000.00 in net income (profit) each year or ($5.83) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

The company employs 767 workers across the globe.

Does Apellis Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.
Read More
How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.

This page (NASDAQ:APLS) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -